Navigation Links
Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
Date:9/19/2007

Prodrugs Generated from Targanta's Novel Drug Discovery Platform

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released detailed data from two studies highlighting the in vitro activity and in vivo efficacy of its proprietary prodrugs in osteomyelitis models. Results are being presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL and represent the first data sets from this proprietary platform.

Osteomyelitis is an acute or chronic bone infection predominantly caused by staphylococci, requiring treatment through prolonged parenteral antibiotic administration and, often, surgical intervention. There are currently no antibiotics approved to treat osteomyelitis, which has been designated by the U.S. Food and Drug Administration (FDA) as a significant unmet medical need. Targanta has developed a novel drug discovery platform through which it tethers bone-targeting bisphosphonates to approved antibiotics to generate molecules that deliver the antibiotics directly to the bone, targeting the site of infection.

In the first study, entitled, "Preparation and In Vitro Evaluation of Fluoroquinolone Prodrugs for the Prevention and Treatment of Osteomyelitis," researchers synthesized a total of 45 bisphosphonated fluoroquinolone prodrugs by tethering ciprofloxacin, gatifloxacin or moxifloxacin to a bisphosphonate via cleavable linkers. The affinity of the prodrugs for bone was determined by exposing individual compounds to a suspension of bovine bone powder. Most were found to bind near quantitatively to bone powder and released the parent fluoroquinolone at various rates. In this in vitro study, the high affinity displayed by the compounds for bone powder and their ability to regenerate active parent compound over time suggests they could be used to concentrate antibacterial fluoroquinolones into the bone via systemic administration.

In
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)... All Patients in Cohort 3 Demonstrated Improvement...e Therapeutic Potential of HspE7, SAN DIEGO, May ...cals,Corporation (TSX: NVN) today announced positi... ongoing Phase 1 clinical trial of its lead produc...aepithelial neoplasia, or,CIN, a precursor to cerv...
(Date:5/9/2008)... TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Ma...side effects. These can include nausea and,vomitin...r, chronic use.,Such symptoms can lead patients to...tions to pain management for physicians. The novel...y acting oral analgesic, provided pain,relief for ...
(Date:5/9/2008)... Boosts Cytopia,s development of early pipeline ca... /- Cytopia Limited,(ASX: C...ti-cancer drug,discovery and development collabora...reement leverages Cytopia,s early stage drug disco...geted therapeutics that is one of the,fastest grow...
(Date:5/8/2008)... MIAMI, May 8 /- Globus Medical, Inc...acturer in the world and a recognized,leader in mo...completion of,enrollment in its SECURE(R)-C Cervic...ce is designed to mimic the normal motion of the s...on as an alternative to fusion in,the treatment of...
Breaking Medicine Technology:Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 2New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 3New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 4Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 2Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 3Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Genetics determine optimal drug dose of common anticoagulant 112 1Genetics determine optimal drug dose of common anticoagulant 112 2YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 1YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 2YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 3YM BIOSCIENCES EUROPEAN PARTNER ONCOSCIENCE AG ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 119 4New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 1New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 2New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 3New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 4New Data Suggest Cymbalta 28R 29 Reduced Pain in Fibromyalgia Patients With and Without Depression 110 5Consequences of online HIV denial 3B and more 120 1Consequences of online HIV denial 3B and more 120 2Consequences of online HIV denial 3B and more 120 3Consequences of online HIV denial 3B and more 120 4
(Date:5/12/2008)...consumers on indoor air quality, ANN ARBOR, Mich....onth,according the Environmental Protection Agency...ng this opportunity to educate consumers on the,im...erious condition. The,EPA states that asthma sent ...n the year 2000, and according to the American Lun...
(Date:5/12/2008)...ors, there exists among the multitude of warrior c... patiently lying in wait to launch their attacks. ...leukemia initiating cells (LICs), these stealth po...apy and undaunted by targeted cancer therapies. Wh...of remission, it is the LICs that bear responsibil...
(Date:5/12/2008)...f-life care for older people in the final stages o...ublished in the May issue of Journal of Clinical N...ementia from suffering from protracted, potentiall...aper, Professor of Nursing for The Open University...a major international public health concern becaus...
(Date:5/12/2008)...Ruth Kluck at Melbournes Walter and Eliza Hall Ins...hanism by which cells destroy themselves. In this ...the cell to self-destruct by puncturing its power ... by the WEHI team. The discovery is an important s...s designed to regulate cell death. , Dr Kluck a...
Breaking Medicine News(10 mins):Health News:Asthma Awareness Month Spawns Healthy Advice 2Health News:Arsenic-based therapy shown to help eradicate leukemia-initiating cells 2Health News:Arsenic-based therapy shown to help eradicate leukemia-initiating cells 3Health News:End-stage dementia patients deserve the same access to palliative care as people with cancer 2Health News:End-stage dementia patients deserve the same access to palliative care as people with cancer 3Health News:Key step in the 'puncture' mechanism of cell death revealed 2
...31 states during the past year, an estimated two-t...tal diseases such as// diabetes, stroke and cancer...state government efforts to curb the overweight ep...rt from the Trust for America's Health. The repo...
...oie, offered to donate nearly 60% of his liver to ...parently did not have any// second thoughts about ...avoie, 54, had been suffering hepatitis C for almo...amaged his liver. There was no option left to reve...
...ealthcare problem, which has tickled the curiosity...es, is also the increasing// numbers of myths doin...rch on the subject of obesity has been conducted f...dy conducted in Britain has painted a dismal scena...
...lesbians and single women as heterosexual couples,....// This call was made by the British Fertility S... wide disparity" on the social criteria used for a...e of treatment. Their recommendations sent to the...
Other Medicine News:Health News:Rise in Obesity Rates in 31 States 2Health News:Rise in Obesity Rates in 31 States 3
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States.
Medicine Products: